Related Experiment Video
Updated: Dec 31, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
MicroRNA-130a reduces drug resistance in breast cancer
Jin Huang1, Min Zhao1, Hongguang Hu1
1Department of Pathology, The Second People's Hospital of Hefei Hefei 230011, Anhui, China.
Objective:
Although the advent of chemotherapy has made some progress in the comprehensive treatment of breast cancer, drug resistance of tumor cells remains to be one of the main challenges for the treatment of breast cancers. Several microRNAs have been implicated in the resistant process, but the role of miR-130a in drug resistance in breast cancer remains unclear. The present study aims to investigate the role and mechanisms of miR-130a in drug resistance in breast cancer cells and tissues.
Patients And Methods:
miR-130a mimics was used to up-regulate miR-130a expression in Doxorubicin-resistant MCF-7/Adr breast cancer cell line, followed by MTT assay and colony formation to determine cell viability and relative colony number. The relationship between the expression of miR-130a and drug resistance was detected by in situ hybridization in the formalin-fixed paraffin-embedded (FFPE) tissues from 50 breast cancer patients before and after Epirubicin-based neoadjuvant chemotherapy.
Results:
Up-regulation of miR-130a level in MCF-7/Adr cells decreased the cell viability and colony number, and reversed Doxorubicin resistance of MCF-7/Adr cells. In breast cancer tissue from patients, the miR-130a level was lower before neoadjuvant chemotherapy than that after neoadjuvant chemotherapy (P < 0.05). Moreover, a significant increase in the expression of miR-130a was observed in breast tumor tissues from patients sensitive to neoadjuvant chemotherapy compared to the patients who were resistant to neoadjuvant chemotherapy (P < 0.05).
Conclusion:
We concluded that miR-130a might weaken drug resistance of human breast cancer cells, and act as an important factor in prediction of therapeutic responses in chemotherapy of breast cancer.
Insights
MicroRNA-130a (miR-130a) may reduce breast cancer drug resistance. Higher miR-130a levels correlate with chemotherapy sensitivity, suggesting its potential as a predictive biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chemotherapy is crucial for breast cancer treatment, but drug resistance remains a significant challenge.
- MicroRNAs (miRNAs) are implicated in drug resistance, yet the specific role of miR-130a in breast cancer is not well understood.
Purpose of the Study:
- To investigate the role and underlying mechanisms of miR-130a in breast cancer drug resistance.
- To explore miR-130a as a potential biomarker for predicting chemotherapy response.
Main Methods:
- Upregulation of miR-130a using mimics in Doxorubicin-resistant MCF-7/Adr cells.
- Assessment of cell viability and colony formation via MTT assay and colony formation assay.
- In situ hybridization analysis of miR-130a expression in patient tissues before and after neoadjuvant chemotherapy.
Main Results:
- Upregulating miR-130a in MCF-7/Adr cells reduced cell viability and reversed Doxorubicin resistance.
- miR-130a levels were lower before than after neoadjuvant chemotherapy in patient tissues.
- Increased miR-130a expression was observed in chemotherapy-sensitive versus resistant breast cancer patients.
Conclusions:
- miR-130a may attenuate drug resistance in human breast cancer cells.
- miR-130a shows potential as a predictive factor for breast cancer chemotherapy response.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:56Treatment Resistant Cancers